The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Serevent     2-(hydroxymethyl)-4-[1- hydroxy-2-[6-(4...

Synonyms: Aeromax, Astmerole, SALMATEROL, Salmeterol, Salmeterolum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aeromax


Psychiatry related information on Aeromax


High impact information on Aeromax

  • The morning dose of salmeterol attenuated the degree of bronchoconstriction at all times (decrease in FEV1 on day 1, 5+/-2 percent; on day 14, 10+/-3 percent; and on day 29, 9+/-3 percent; P=0.10) [1].
  • The role of long-acting beta2-adrenergic-receptor agonists, such as salmeterol, needs to be defined [10].
  • We compared a new long-acting, inhaled beta 2-adrenoceptor agonist, salmeterol, with a short-acting beta 2-agonist, albuterol, in the treatment of mild-to-moderate asthma [11].
  • There was a significant increase in FEV1 one hour after the inhalation of salmeterol (P = 0.006), which did not differ significantly on days 0, 28, and 56 of the treatment period (increase, 9.8, 9.4, and 8.8 percent of predicted FEV1, respectively; P = 0.91) [12].
  • We investigated the long-term effects of the beta 2 agonist salmeterol on bronchodilation and on airway hyperresponsiveness to the bronchoconstrictive agent methacholine in mild asthma [12].

Chemical compound and disease context of Aeromax


Biological context of Aeromax

  • Salmeterol remained effective in terms of disease control, with a significant improvement in morning PEFR compared with placebo that was maintained over the 4 week treatment period.(ABSTRACT TRUNCATED AT 250 WORDS)[18]
  • After a 2 week run-in without beta-2 agonists, 17 asthmatic patients (mean [SE] age 34 [3] years, mean forced expiratory volume in 1 s [FEV1] 64 [2.7]% of predicted) were randomised to receive salmeterol 50 micrograms twice daily or placebo for 4 weeks in a double-blind cross-over fashion [18].
  • In this respect, there is strong evidence for the existence of specific additional binding sites (exosites) for salmeterol and related compounds, and that exosites exist on non-ligand recognition regions of the beta 2-adrenoceptor protein [19].
  • Additionally, salmeterol did not affect the maximal heart rate achieved during the test as compared with the placebo [20].
  • RESULTS: There was sustained and significant improvement (P < .001) over baseline in all measures of asthma control in subjects receiving salmeterol, regardless of Arg16Gly genotype [21].

Anatomical context of Aeromax


Associations of Aeromax with other chemical compounds


Gene context of Aeromax


Analytical, diagnostic and therapeutic context of Aeromax


  1. Effect of long-term salmeterol treatment on exercise-induced asthma. Nelson, J.A., Strauss, L., Skowronski, M., Ciufo, R., Novak, R., McFadden, E.R. N. Engl. J. Med. (1998) [Pubmed]
  2. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., Maden, C. Lancet (2003) [Pubmed]
  3. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Korosec, M., Novak, R.D., Myers, E., Skowronski, M., McFadden, E.R. Am. J. Med. (1999) [Pubmed]
  4. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Dowling, R.B., Rayner, C.F., Rutman, A., Jackson, A.D., Kanthakumar, K., Dewar, A., Taylor, G.W., Cole, P.J., Johnson, M., Wilson, R. Am. J. Respir. Crit. Care Med. (1997) [Pubmed]
  5. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Maris, N.A., de Vos, A.F., Dessing, M.C., Spek, C.A., Lutter, R., Jansen, H.M., van der Zee, J.S., Bresser, P., van der Poll, T. Am. J. Respir. Crit. Care Med. (2005) [Pubmed]
  6. Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease. Kardos, P., Wencker, M., Glaab, T., Vogelmeier, C. Am. J. Respir. Crit. Care Med. (2007) [Pubmed]
  7. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. Nathan, R.A., Dorinsky, P., Rosenzweig, J.R., Shah, T., Edin, H., Prillaman, B. The Journal of asthma : official journal of the Association for the Care of Asthma. (2003) [Pubmed]
  8. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Gongora, H.C., Wisniewski, A.F., Tattersfield, A.E. Am. Rev. Respir. Dis. (1991) [Pubmed]
  9. Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. Durham, M.C. Proceedings (Baylor University. Medical Center) (2004) [Pubmed]
  10. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. Simons, F.E. N. Engl. J. Med. (1997) [Pubmed]
  11. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. Pearlman, D.S., Chervinsky, P., LaForce, C., Seltzer, J.M., Southern, D.L., Kemp, J.P., Dockhorn, R.J., Grossman, J., Liddle, R.F., Yancey, S.W. N. Engl. J. Med. (1992) [Pubmed]
  12. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. Cheung, D., Timmers, M.C., Zwinderman, A.H., Bel, E.H., Dijkman, J.H., Sterk, P.J. N. Engl. J. Med. (1992) [Pubmed]
  13. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Kemp, J.P., Dockhorn, R.J., Busse, W.W., Bleecker, E.R., Van As, A. Am. J. Respir. Crit. Care Med. (1994) [Pubmed]
  14. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children. Verberne, A.A., Hop, W.C., Bos, A.B., Kerrebijn, K.F. J. Allergy Clin. Immunol. (1993) [Pubmed]
  15. Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor. McCrea, K.E., Hill, S.J. Mol. Pharmacol. (1996) [Pubmed]
  16. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. Cazzola, M., Donner, C.F. Drugs (2000) [Pubmed]
  17. Tiotropium bromide. Hvizdos, K.M., Goa, K.L. Drugs (2002) [Pubmed]
  18. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Grove, A., Lipworth, B.J. Lancet (1995) [Pubmed]
  19. Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Coleman, R.A., Johnson, M., Nials, A.T., Vardey, C.J. Trends Pharmacol. Sci. (1996) [Pubmed]
  20. The effects of salmeterol on power output in nonasthmatic athletes. McDowell, S.L., Fleck, S.J., Storms, W.W. J. Allergy Clin. Immunol. (1997) [Pubmed]
  21. Salmeterol response is not affected by beta(2)-adrenergic receptor genotype in subjects with persistent asthma. Bleecker, E.R., Yancey, S.W., Baitinger, L.A., Edwards, L.D., Klotsman, M., Anderson, W.H., Dorinsky, P.M. J. Allergy Clin. Immunol. (2006) [Pubmed]
  22. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. Eickelberg, O., Roth, M., Lörx, R., Bruce, V., Rüdiger, J., Johnson, M., Block, L.H. J. Biol. Chem. (1999) [Pubmed]
  23. Potential masking effects of salmeterol on airway inflammation in asthma. Mcivor, R.A., Pizzichini, E., Turner, M.O., Hussack, P., Hargreave, F.E., Sears, M.R. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
  24. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Taylor, D.A., Jensen, M.W., Aikman, S.L., Harris, J.G., Barnes, P.J., O'Connor, B.J. Am. J. Respir. Crit. Care Med. (1997) [Pubmed]
  25. Effects of salmeterol on smooth muscle versus inflammatory outcomes. Lipworth, B.J., Jackson, C.M. J. Allergy Clin. Immunol. (2003) [Pubmed]
  26. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. Lemanske, R.F., Sorkness, C.A., Mauger, E.A., Lazarus, S.C., Boushey, H.A., Fahy, J.V., Drazen, J.M., Chinchilli, V.M., Craig, T., Fish, J.E., Ford, J.G., Israel, E., Kraft, M., Martin, R.J., Nachman, S.A., Peters, S.P., Spahn, J.D., Szefler, S.J. JAMA (2001) [Pubmed]
  27. Combined salmeterol and fluticasone for COPD. MacAllister, R. Lancet (2003) [Pubmed]
  28. Oral montelukast versus inhaled salmeterol to prevent exercise-induced bronchoconstriction. Grieco, A.J., Burstein-Stein, J. Ann. Intern. Med. (2000) [Pubmed]
  29. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Palmqvist, M., Ibsen, T., Mellén, A., Lötvall, J. Am. J. Respir. Crit. Care Med. (1999) [Pubmed]
  30. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. Nelson, H.S., Chapman, K.R., Pyke, S.D., Johnson, M., Pritchard, J.N. J. Allergy Clin. Immunol. (2003) [Pubmed]
  31. Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway. Taouil, K., Hinnrasky, J., Hologne, C., Corlieu, P., Klossek, J.M., Puchelle, E. J. Biol. Chem. (2003) [Pubmed]
  32. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. Nie, M., Corbett, L., Knox, A.J., Pang, L. J. Biol. Chem. (2005) [Pubmed]
  33. Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. Tran, T.M., Friedman, J., Qunaibi, E., Baameur, F., Moore, R.H., Clark, R.B. Mol. Pharmacol. (2004) [Pubmed]
  34. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Usmani, O.S., Ito, K., Maneechotesuwan, K., Ito, M., Johnson, M., Barnes, P.J., Adcock, I.M. Am. J. Respir. Crit. Care Med. (2005) [Pubmed]
  35. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Pang, L., Knox, A.J. Am. J. Respir. Cell Mol. Biol. (2000) [Pubmed]
  36. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. Pang, L., Knox, A.J. FASEB J. (2001) [Pubmed]
  37. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Calhoun, W.J., Hinton, K.L., Kratzenberg, J.J. Am. J. Respir. Crit. Care Med. (2001) [Pubmed]
WikiGenes - Universities